We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Watchstone Group Plc | LSE:WTG | London | Ordinary Share | GB00BYNBFN51 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 52.10 | 50.00 | 54.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMWTG
RNS Number : 6093O
Watchstone Group PLC
31 January 2019
Watchstone Group plc
("Watchstone" or the "Group")
Pre-close trading update
Watchstone Group plc (LON:WTG) today issues a pre-close trading update ahead of its results for the year ended 31 December 2018.
Revenue (unaudited): 2018 2017 year ended 31 December Healthcare services GBP30.0m (C$51.8m) GBP30.5m (C$51.1m) ------------------- ------------------- ingenie GBP7.7m GBP14.4m ------------------- ------------------- Total GBP37.7m GBP44.9m ------------------- -------------------
Cash and term deposits on 31 December 2018 totalled GBP50.1m (GBP58.4m as at 30 June 2018) excluding the GBP50.2m in escrow pending resolution or determination of the claim issued by Slater & Gordon (UK) 1 Limited ("Slater & Gordon Claim").
Healthcare services:
Healthcare services consists of our Canadian ptHealth clinics business and InnoCare, our clinic software, referral network and managed services business. In the year, the Healthcare services division grew revenues in local currency despite the sale and conversion to a managed service offering of one of its underperforming clinics. However, adverse movements in the Canadian Dollar relative to Sterling has resulted in lower revenues being recorded overall in Sterling.
During the second half of 2018, ptHealth was appointed as the Canadian Arthritis Society's national physiotherapy provider and also became the first physiotherapy provider officially certified as a Great Place to Work(R) by the Great Place to Work(R) Institute Canada.
As anticipated, a significant proportion (39%, C$4.23m (approximately GBP2.5m)) of the preference shares in the business have been redeemed in the year. Profitability is expected to be broadly flat relative to 2017 however a significant restructuring of the clinic business has been completed in the year which more closely aligns costs to revenues and should create more optimal conditions for profitable growth.
ingenie:
As previously described, challenging trading conditions have continued to further impact retail volumes. A number of initiatives have been undertaken to address these issues including the recent broadening of underwriting partnerships and this has seen positive, albeit early, trends. Further structural changes to the business continue which are anticipated to revive the retail competitiveness of the offering during H1 2019.
The ANWB programme is performing well and underlines the credibility and relevance of ingenie's business to business offering. ingenie's B2B pipeline is strong with a variety of opportunities being pursued with vigour.
Central costs and overall results:
Central costs were rationalised at the end of 2017 and this is reflected in materially lower expenditure during 2018.
Legacy matters:
The Slater & Gordon Claim is ongoing and the disclosure process commenced in December 2018. Our position remains that Slater & Gordon's allegations of deceit and the associated breach of warranty claim are wholly without merit and should never have been advanced. During the year, significant costs have been incurred in defence of this claim and we continue to bolster the provision for legal costs in anticipation of a trial commencing in October 2019. In parallel, we continue to pursue any deferred consideration due from Slater & Gordon in respect of the disposal of the PSD.
The SFO investigation continues and we are cooperating fully. It remains the only regulatory inquiry to which the Group is subject.
2019 outlook:
2019 will be an important year for the Group both in terms of growing its operating businesses and dealing with the Group's legacy issues as efficiently as possible.
For further information:
Watchstone Group plc Tel: 03333 448048 Peel Hunt LLP, Nominated Adviser and Broker Tel: 020 7418 8900 Dan Webster
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
TSTLIFIILVILVIA
(END) Dow Jones Newswires
January 31, 2019 02:01 ET (07:01 GMT)
1 Year Watchstone Chart |
1 Month Watchstone Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions